Synthetic Biologics, Inc. (SYN)

Synthetic Biologics, Inc. (SYN) — VMCI valuation read

SYN screens at VMCI 35/100, a 16-point gap below the Healthcare sector median (50). For a mid-cap Synthetic Biologics, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

SYN has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: SYN trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.1x leaves covenant headroom, which sets the rate-cycle exposure for Synthetic Biologics, Inc..

SYN fell 2.9% over the trailing 7 days, with a -4.6% read on a 30-day basis.